BIBLIOGRAFÍA

1. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986; 315: 161-8.

2. Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis 1985; 151: 832-9.

3. Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, Wang SP. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161: 618-25.

4. Kuo CC, Chen HH, Wang SP, Grayston JT. Identification of a new group of Chlamydia psittaci strains called TWAR. J Clin Microbiol 1986; 24: 1034-7.

5. Meijer A, Kwakkel GJ, de Vries A, Schouls LM, Ossewaarde JM. Species identification of Chlamydia isolates by analyzing restriction fragment length polymorphism of the 16S-23S rRNA spacer region. J Clin Microbiol 1997; 35: 1179-83.

6. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98: 300-7.

7. Peeling RW, Brunham RC. Chlamydiae as pathogens: new species and new issues. Emerg Infect Dis 1996; 2: 307-19.

8. Schachter J, Dawson CR. Psittacosis-lymphogranuloma venereum agents/tric agents. En: Lennette EH, Schmidt NJ, editores. Diagnostic procedures for viral, rickettsial and chlamydial infections. 5ta. ed. American Public Health Association Inc.; 1979: 1021-59.

9. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 1993; 13: 1501-4.

10. Campbell LA, Perez M, Hamilton DJ, Kuo CC, Grayston JT. Detection of Chlamydia pneumoniae by polymerase chain reaction. J Clin Microbiol 1992; 30: 434-9.

11. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-9.

12. Boman J, Hammerschlag MR. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev 2002; 15: 1-20.

13. Segal BL. Distribución y relación de la aterosclerosis con la enfermedad cardiaca coronaria. En: Likoff W, Moyer JH, editores. La cardiopatía coronaria. Barcelona: Editorial Científico-Médica; 1967: 163-9.

14. Arbustini E, Morbini P, Dal Bello B, Prati F, Specchia G. From plaque biology to clinical setting. Am Heart J 1999; 138: S55-S60.

15. Muhlestein JB. The link between Chlamydia pneumoniae and atherosclerosis. Infect Med 1997; 14: 380-2.

16. Campbell LA, Kuo CC, Grayston JT. Chlamydia pneumoniae and cardiovascular disease. Emerg Infect Dis 1998; 4: 571-6.

17. Orfila JJ. Seroepidemiological evidence for an association between Chlamydia pneumoniae and atherosclerosis. Atherosclerosis 1998; 140: S11-S15.

18. Taylor-Robinson D. Chlamydia pneumoniae in vascular tissue. Atherosclerosis 1998; 140: S21-S24.

19. Wong YK, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. Heart 1999; 81: 232-8.

20. Binder S, Levitt AM, Hughes JM. Preventing emerging infectious diseases as we enter the 21st century: CDC’s strategy. Public Health Reports 1999; 114: 130-4.

21. Grayston JT. Does Chlamydia pneumoniae cause atherosclerosis? Arch Surg 1999; 134: 930-4.

22. Sullivan JL, Weinberg ED. Iron and the role of Chlamydia pneumoniae in heart disease. Emerg Infect Dis 1999; 5: 724-6.

23. Gupta S, Camm AJ. Chlamydia pneumoniae and coronary heart disease. BMJ 1997; 314: 1778-9.

24. incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555-61.

25. Ramírez JA et al. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 1996; 125: 979-82.

26. Grayston JT, Campbell LA. The role of Chlamydia pneumoniae in atherosclerosis. Clin Infect Dis 1999; 28: 993-4.

27. Thomas M, Wong Y, Thomas D, Ajaz D, Tsang V, Gallagher PJ, et al. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (stary grading) of associated atherosclerotic plaque. Circulation 1999; 99: 2733-6.

28. Ramos PM, Ortega F, Samaniego J, Díaz R. Microscopía electrónica, Chlamydia pneumoniae y aterosclerosis. Medicina Clínica 1999; 112: 277-8.

29. Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence RD, Lee MJ, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995; 92: 3397-400.

30. Wissler RW. Significance of Chlamydia pneumoniae (TWAR) in atherosclerotic lesions. Circulation 1995; 92: 3376.

31. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68-72.

32. Puolakkainen M, Kuo CC, Shor A, Wang SP, Grayston JT, Campbell LA. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol 1993; 31: 2212-4.

33. Cook PJ, Honeybourne D, Lip GYH, Beevers DG, Wise R. Chlamydia pneumoniae and acute arterial thrombotic disease. Circulation 1995; 92: 3148-9.

34. Miyashita N, Toyota E, Sawayama T, Matsumoto A, Mikami Y, Kawai N, et al. Association of chronic infection of Chlamydia pneumoniae and coronary heart disease in the japanese. Intern Med 1998; 37: 913-6.

35. Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang SP, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med 1993; 95: 499-504.

36. Stenvinkel P, Heimbürger O, Jogestrand T, Kärnell A, Samuelsson A. Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure? Kidney Int 1999; 55: 2531-2.

37. Jackson LA, Campbell LA, Schmidt RA, Kuo CC, Cappuccio AL, Lee MJ, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma. Am J Pathol 1997; 150: 1785-90.

38. Marrie TJ, Grayston JT, Wang SP, Kuo CC. Pneumonia associated with the TWAR strain of Chlamydia. Ann Intern Med 1987; 106: 507-11.

39. Laitinen K, Laurila A, Pyhälä L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997; 65: 4832-5.

40. Bartel C, Maass M, Bein G, Malisius R, Brill N, Bechtel M, et al. Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation 1999; 99: 879-82.

41. Jantos CA, Nesseler A, Waas W, Baumgärtner W, Tillmanns H, Haberbosch W. Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease. Clin Infect Dis 1999; 28: 988-92.

42. Wong YK, Thomas M, Tsang V, Gallagher PJ, Ward ME. The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery. J Am Coll Cardiol 1999; 33: 152-6.

43. Hammerschlag MR. Current knowledge of Chlamydia pneumoniae and atherosclerosis. Eur J Clin Microbiol Infect Dis 1998; 17: 305-8.

44. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31: 827-32.

45. Gurfinkel E. Chlamydia pneumoniae in redo and first-time coronary artery bypass graft surgery. J Am Coll Cardiol 1999; 34: 953-4.

46. Capron L. Peut-on attraper un infarctus? La Recherche 1997; 294: 32-4.

47. Fang JC, Kinlay S, Kundsin R, Ganz P. Chlamydia pneumoniae infection is frequent but not associated with coronary arteriosclerosis in cardiac transplant recipients. Am J Cardiol 1998; 82: 1479-83.

48. Coles KA, Plant AJ, Riley TV, Smith DW, McQuillan BM, Thompson PL. Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis. Am J Cardiol 1999; 84: 825-8.

49. Markus HS, Sitzer M, Carrington D, Mendall M, Steinmetz. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerotic. Circulation 1999; 100: 832-7.

50. Hoffmeister A, Rothenbacher D, Wanner P, Bode G, Persson K , Hombach V, et al. Seropositivity to chlamydial lipopolysaccharide and chlamydia pneumoniae, systemic inflammation and stable coronary artery disease: Negative results of a case-control study. J Am Coll Cardiol 2000; 35: 112-8.

51. Dowell SF, Boman J, Carlone GM, Fields BS, Guarner J, Hammerschlag MR, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA), and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33: 492-503.

52. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 369-76.

53. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.

54. Noll G. Pathogenesis of atherosclerosis: a possible relation to infection. Atherosclerosis 1998; 140: S3-S9. 

55. Godzik KL, O’Brien ER, Wang SK, Kuo CC. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 1995; 33: 2411-4.

56. Yamashita K, Ouchi K, Shirai M, Gondo T, Nakazawa T, Ito H. Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke 1998; 29: 773-8.

57. Blasi F, Cosentini R, Raccanelli R, Massari FM. A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. Chest 1997; 112: 309-12.

58. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression. Circulation 1999; 100: 1369-73.

59. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-6.

60. Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Morrison RP, Byrne GI. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis 1999; 180: 780-90.

61. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Chlamydia pneumoniae antibodies and serum lipids in Finnish men: cross sectional study. BMJ 1997; 314: 1456-7.

62. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 2910-3.

63. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747-53.

64. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001; 89: 244-50.

65. Krüll M, Klucken AC, Wuppemann FN, Fuhrmann O, Magerl C, Seybold J, et al. Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. J Immunol 1999; 162: 4834-41.

66. Bulut Y, Faure E, Thomas L, Karahashi H, Michelsen KS, Equils O, et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 2002; 168: 1435-40.

67. Jantos CA, Krombach C, Wuppermann FN, Gardemann A, Bepler S, Asslan H, et al. Antibody response to the 60-kDa heat-shock protein of Chlamydia pneumoniae in patients with coronary artery disease. J Infect Dis 2000; 181: 1700-5.

68. Ciervo A, Visca P, Petrucca A, Biasucci LM, Maseri A, Cassone A. Antibodies to 60-kilodalton heat shock protein and outer membrane protein 2 of Chlamydia pneumoniae in patients with coronary heart disease. Clin Diag Lab Immunol 2002; 9: 66-74.

69. Ericson K, Saldeen TGP, Lindquist O, Påhlson C, Mehta JL. Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. Circulation 2000; 101: 2568-71.

70. Woolcott OO, Sánchez LM, Ruiz E, Maguiña J, Carrera R, Aronés S, et al. Detección de Chlamydia pneumoniae en lesiones ateroscleróticas asociadas a infarto miocárdico agudo. An Fac Med 2001; 62: 325-31.

71. Gurfinkel E, Bazovich G. Chlamydia pneumoniae: inflammation and instability of the atherosclerosis plaque. Atherosclerosis 1998; 140: S31-S35.

72. Bauriedel G, Welsch U, Likungu JA, Welz A, Lüderitz B. Chlamydia pneumoniae in koronarem plaquegewebe: Vermehrter nachweis bei akutem koronarsyndrom. Dtsch med Wschr 1999; 124: 375-80.

73. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999; 180: 238-41.

74. Grayston JT. Antibiotic tratment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. Circulation 1998; 97: 1669-70.

75. Gura T. Infection: A cause of artery-clogging plaques? Science 1998; 281: 35-7.

76. Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL, et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998; 97: 1675-9.

77. Kuvin JT, Kimmelstiel CD. Infectious causes of atherosclerosis. Am Heart J 1999; 137: 216-26.

78. Blasi F, Denti F, Erba M, Cosentini R, Raccanelli R, Rinaldi A, et al. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 1996; 34: 2766-9.

79. Saikku P, Mattila K, Nieminen MS, Huttunen JK, Leinonen M, Ekman MR, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-6.

80. Sutton GC, Demakis JA, Anderson TO, Morrissey RA. Serological evidence of a sporadic outbreak in Illinois of infection by Chlamydia (psittacosis-LGV agent) in patients with primary myocardial disease and respiratory disease. Am Heart J 1971; 81: 597-607.

81. Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman MR, Manninen V, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273-8.

82. Mazzoli S, Tofani N, Semplici F, et al. Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up. Am Heart J 1998; 135: 15-20.

83. Nieto FJ, Folsom AR, Sorlie PD, Grayston JT, Wang SP, Chambless LE. Chlamydia pneumoniae infection and incident coronry heart disease. Am J Epidemiol 1999; 150: 149-56.

84. Strachan DP, Carrington D,  Mendall MA, Ballam L,  Morris J, Butland BK, et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ 1999; 318: 1035-40.

85. Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med 1999; 131: 573-7.

86. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99: 1161-4.

87. Abdelmouttaleb I, Danchin N, Ilardo C, Aimone-Gastin I, Angioï M, Lozniewski A, et al. C-reactive protein and coronary artery disease: Additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 1999; 137: 346-51.

88. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-60.

89. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061-5.

90. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia and heart disease linked through antigenic mimicry. Science 1999; 283: 1335-9.

91. Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Banerjee T, Maiwald M, et al. Recent infection as a risk factor for cerebrovascular ischemia. Stroke 1995; 26: 373-9.

92. Bova IY, Bornstein NM, Korczyn AD. Acute infection as a risk factor for ischemic stroke. Stroke 1996; 27: 2204-6.

93. Grau AJ, Buggle F, Ziegler C, Schwarz W, Meuser J, Tasman AJ, et al. Association between acute cerebrovascular ischemia and chronic and recurrent infection. Stroke 1997; 28: 1724-9.

94. Grau AJ, Buggle F, Becher H. Zimmermann E, Spiel M, Fent T, et al. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia. Neurology 1998; 50: 196-203.

95. Wimmer MLJ, Sandmann-Strupp R, Saikku P, Haberl RL. Association of Chlamydial infection with cerebrovascular disease. Stroke 1996; 27: 2207-10.

96. Cook PJ, Honeybourne D, Lip GYH, Beevers G, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia. The West Birmingham Stroke Project. Stroke 1998; 29: 404-10.

97. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not Cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease. A prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999; 30: 299-305.

98. Grau AJ, Buggle F, Steichen-Wiehn C, Heindl S, Banerjee T, Seitz R, et al. Clinical and biochemical analysis in infection-associated stroke. Stroke 1995; 26: 1520-6.

99. Hammerschlag MR. Activity of quinolones against Chlamydia pneumoniae. Drugs 1999:58: Suppl 2: 78-81.

100.Schussheim AE, Fuster V. Antibiotics for myocardial infarction? Drugs 1999; 57: 283-91.

101.Roblin PM, Reznik T, Kutlin A, Hammerschlag MR. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 1999; 43: 2806-7.

102.Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.

103.Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-7.

104.Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999; 281: 427-31.

105.Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6.

106.Bauriedel G, Hutter R, Lüderitz B. Azithromycin, Chlamydia pneumoniae, and intimal thickening. Circulation 1998; 98: 2357.

107.Rothstein NM, Quinn TC, Madico G, Gaydos CA, Lowenstein CJ. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J Infect Dis 2001; 183: 232-8.

108.Giménez-Sánchez F,  Butler JC,  Jernigan DB,  Strausbaugh LJ,  Slemp CC,  Perilla MJ, et al. Treating cardiovascular disease with antimicrobial agents: A survey of knowledge, attitudes, and practices among physicians in the United States. Clin Infect Dis 2001; 33: 171-6.

109.Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis 1999; 5: 281-4. 


REGRESAR AL ARTÍCULO

Regresar